Allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

External organisations

  • Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom
  • Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.

Abstract

Allogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse.

Details

Original languageEnglish
Pages (from-to)8-15
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number1
Publication statusPublished - Jan 2015

Keywords

  • Adult, Chromosome Aberrations, Disease Management, Drug Resistance, Neoplasm, Graft vs Leukemia Effect, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Myeloablative Agonists, Neoplastic Stem Cells, Recurrence, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, Treatment Failure, Journal Article, Review